NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2011 /PRNewswire/ -- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) announced today that NASDAQ has removed TLCR from the NASDAQ Biotechnology Index(R) (Nasdaq: NBI) in anticipation of the company's pending acquisition by Grifols S.A. The change takes effect Feb. 15 prior to the market's opening.
This customary NASDAQ policy is intended to provide stockholders with advance notice of a company's anticipated merger or acquisition in order to allow them time to sell their position. If the acquisition is not completed, NASDAQ plans to reinstate Talecris in the Biotechnology Index during the following semi-annual re-ranking of securities. Talecris was initially added to the NASDAQ Biotechnology Index on May 24, 2010.
The Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com